Industry Spotlight: STALICLA
STALICLA is a Swiss clinical stage biopharmaceutical company leading omics-based precision medicine drug development for patients with neurodevelopmental disorders (NDDs), with a first application in Autism Spectrum Disorder (ASD). STALICLA is on a unique mission to identify clinically actionable patient subgroups and develop tailored treatments for those most impaired by their symptoms.
Just as the lived experiences of people diagnosed with neurodevelopmental disorders (NDDs) are unique, many NDDs that currently fall under the same disease category have very different biological bases. STALICLA recognizes that heterogeneity and is leveraging biomedical and clinical data to gain new insights into biologically distinct patient populations and treatments to match – it has developed first-in-class systems biology and AI technology that harnesses patients’ biological signatures along with complex data analysis to identify tailored treatment options that result in measurable clinical improvements.
STALICLA’s unique drug discovery platform uses systems biology and machine learning to integrate and analyze large, omics-based datasets along with clinical information from variable populations of patients with NDDs to identify subgroups of those patients who may benefit from corresponding candidate drugs.
STALICLA completes first stage trials for the first precision medicine in Autism Spectrum Disorder
The goal of this phase 1b, double-blind, placebo-controlled study was to evaluate the safety, tolerability, and pharmacokinetics of a two-week oral treatment with STP1 in a subgroup of patients with ASD. In addition to showing good safety and tolerability profiles, and dose-dependent target engagement, STP1 treatment resulted in positive signals in clinical markers of neurological and behavioral function, including improved processing speed and crystallized cognition composite. Read more on this study on STALICLA website.